SEPTEMBER 20, 2007 - CITRA ANTICOAGULANTS, INC. AND H.A.C. PHARMA SIGN MARKETING AGREEMENT FOR PROMOTION OF LOXXIT™ CATHETER LOCK SOLUTION TO THE EMEA MARKET

Braintree, Massachusetts USA - Citra Anticoagulants, Inc. a leading, developer and worldwide distributor of citrate-based anticoagulants used in dialysis, reconstructive, and orthopaedic markets, reported today that it has signed an exclusive Marketing Services Agreement with H.A.C. Pharma for LOXXIT™ Catheter Lock Solution.

The Agreement appoints H.A.C. Pharma as Citra's sole representative to promote the marketing and sales activities of LOXXIT™ Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, to distributors in Europe, the Middle East, and Africa.

H.A.C. Pharma is headquartered in Caen, France. It is a pharmaceutical marketing company focused on specialty therapeutic areas. The company commercializes drugs, medical devices, and food supplements for medical purposes in France and throughout the world. For more information and how to contact H.A.C. Pharma, visit www.hacpharma.com.

Ronald H. Lewis, Ph.D., President of Citra Anticoagulants, Inc. said, "We are extremely excited about partnering our LOXXIT™ Catheter Lock Solution with H.A.C. Pharma in the EMEA medical arena. LOXXIT™ is an excellent preventive-action product and H.A.C. Pharma has a strong sales/marketing team committed to exceeding customer expectations. The future for the combination of LOXXIT™ with H.A.C. Pharma is extremely bright."

Citra Anticoagulants, Inc. is a privately held company headquartered in the United States, 10 minutes outside of Boston, Massachusetts. Team Citra embraces the mission to develop and market safe and effective citrate-based anticoagulants for the medical community, while providing outstanding customer service. Citra's products are used in many different applications: from the anticoagulant of choice in the preparation of platelet rich plasma, which is used as an aid in wound healing, to the anticoagulant of choice for the collection of granulocytes which are used to support patients undergoing cancer therapy, and to a superb catheter lock solution where the product functions as an anticoagulant and an antimicrobial agent.

Citra's products are manufactured under Current Good Manufacturing Practices (cGMPs). The manufacturing facility is registered with the United States Food & Drug Administration as a Drug and Medical Device Facility and is EN ISO 13485:2003 certified (Reg. No. 44 221 07 345443-001) by TUV NORD.

Contact:
Citra Anticoagulants, Inc.
Ronald H. Lewis, Ph.D., President
Adrienne Summers, Team Customer
e-mail protected from spam bots
Tel: 781-848-2174
800-299-3411(USA only)
Fax: 781-848-6781


_________________________________________________________________________________

SEPTEMBER 20, 2007 - CITRA ANTICOAGULANTS ANNOUNCES CE MARK APPROVAL FOR LOXXIT™ CATHETER LOCK SOLUTION

Citra Anticoagulants, Inc. a leading, developer and worldwide distributor of citrate-based anticoagulants reported today that it has received CE Mark approval for LOXXIT™ Catheter Lock Solution. This regulatory achievement clears the way for Citra to market and distribute this product throughout the European Union and in other countries that recognize the CE Mark.

LOXXIT™ Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, 5 mL, is a sterile solution that prevents the coagulation of blood, eliminates the growth of microorganisms in any type of intravenous catheter, and prevents biofilm formation because it eliminates the growth of bacteria, yeast, and fungi in the catheter lumen. LOXXIT™ is a preventive-action product and was designed to prevent problems from occurring rather than treating problems that have occured.

In September 2007, Citra signed an exclusive Marketing Services Agreement with H.A.C. Pharma as the sole representative to promote the marketing and sales activities of LOXXIT™ Catheter Lock Solution to distributors in Europe, the Middle East, and Africa.

For more information on LOXXIT™ Catheter Lock Solution, contact H.A.C. Pharma if you are located in Europe, the Middle East, or Africa, or contact Citra Anticoagulants, Inc. for the rest of the world.

About Citra Anticoagulants

Headquartered in Braintree, Massachusetts, 10 minutes outside of Boston, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more information about Citra and our products, visit our website at www.CitraAnticoagulants.com.

Team Citra embraces the mission to develop and market safe and effective citrate-based anticoagulants for the medical community, while providing outstanding customer service. Citra's products are used in many different applications: from anticoagulant of choice in the preparation of platelt rich plasma, which is used as an aid in wound healing, to the anticoagulant of choice for the collection of granulocytes which are used to support patients undergoing cancer therapy, and to a superb catheter lock solution where the product functions as an anticoagulant and an antimicrobial agent.

About H.A.C. Pharma

H.A.C. Pharma is headquartered in Caen, France. It is a pharmaceutical marketing company focused on specialty therapeutic areas. The company commercializes drugs, medical devices, and food supplements for medical purposes in France and throughout the world. For more information and how to contact H.A.C. Pharma, visit www.hacpharma.com.

Contact:
Citra Anticoagulants, Inc.
Ronald H. Lewis, Ph.D., President
Adrienne Summers, Team Customer
e-mail protected from spam bots
Tel: 781-848-2174
800-299-3411(USA only)
Fax: 781-848-6781


_________________________________________________________________________________

FEBRUARY 4, 2007 - CITRA ANTICOAGULANTS ANNOUNCES CE MARK APPROVAL FOR NOCLOT-400™ ANTICOAGULANT CITRATE DEXTROSE SOLUTION, SOLUTION A, ACD-A, U.S.P., 4 MILLILITERS

Citra Anticoagulants, Inc. announces that noClot-400™ Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., 4 milliliters known as ACD-A, has CE mark approval for use in the extracorporeal blood processing with Autologous Platelet Rich Plasma (PRP) Systems in the production of platelet rich plasma.

BRAINTREE, Mass. - Citra Anticoagulants, Inc. announces its parent company, Cytosol Laboratories, Inc., has received U.S. Food and Drug Administration (FDA) approval for NO CLOT 50^®  Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., commonly known as ACD-A, for use in the extracorporeal blood processing with Autologous Platelet Rich Plasma (PRP) Systems in the   production of platelet rich plasma.  NO CLOT 50^® is the anticoagulant of choice to prevent clotting of the whole blood during the extracorporeal blood processing with Autologous PRP Systems.

NO CLOT 50^®  is a United States Pharmacopeia formulated product containing 50 milliliters of ACD-A.  NO CLOT 50^®   prevents the coagulation of blood by virtue of its citrate ion's ability to chelate the ionized calcium present in blood to form a non-ionized calcium-citrate complex. When the total dose of citrate ions is greater than the total amount of ionized calcium, blood clotting is prevented.

NO CLOT 50^® is marketed and distributed exclusively by Citra Anticoagulants, Inc.

Headquartered in Braintree, Massachusetts, Citra Anticoagulants, Inc., is a wholly-owned subsidiary of Cytosol Laboratories, Inc., a privately held company, which develops and manufactures sterile, medical solutions.  Citra Anticoagulants markets and distributes various citrate-based anticoagulants to a multitude of markets within the medical community.

BRAINTREE, Mass. - Cytosol Laboratories, Inc. announces it has received U.S. Food and Drug Administration (FDA) approval for TRICITRASOL^® Anticoagulant Sodium Citrate Concentrate, 46.7% Sodium Citrate, for use in granulocytapheresis.   TRICITRASOL is the critical, citrate-based anticoagulant used in the collection of granulocytes from normal, blood donors. The harvested granulocytes are used in the treatment of cancer patients.

Since TRICITRASOL was voluntarily recalled in April 2000 for not having appropriate FDA approval, the product has been available for use in granulocytapheresis procedures on a written prescription basis only. The FDA approval of Cytosol Laboratories' NDA eliminates the need for a doctor to use the "triCitrasol Medical Necessity Qualification Form" to procure the product.

TRICITRASOL contains the highest concentration of citrate ion of any product that has received FDA approval. TRICITRASOL prevents the coagulation of blood by virtue of the citrate ion's ability to chelate ionized calcium present in blood to form a non-ionized calcium-citrate complex. When the total dose of citrate ions is greater than the total amount of ionized calcium, blood clotting is prevented.

TRICITRASOL is marketed and distributed exclusively by Citra Anticoagulants, Inc., a wholly-owned subsidiary of Cytosol Laboratories, Inc.

About Cytosol Laboratories

Headquartered in Braintree, Mass., Cytosol Laboratories, Inc., a privately held company, develops and manufactures sterile, medical solutions for third parties. Cytosol has two wholly-owned subsidiaries, Citra Anticoagulants, Inc. and enCyte Systems, Inc.   Citra Anticoagulants markets and distributes citrate-based anticoagulants to the medical community. EnCyte Systems markets and distributes medical products that bio-chemically modify red blood cells and medical products that preserve blood cells.

Contact:
Citra Anticoagulants, Inc.
Ronald H. Lewis, Ph.D., President
781-848-2174